A phase II study of local therapy only (stereotactic radiosurgery and or surgery) for treatment of up to 5 brain metastases from HER2+ breast cancer
For patients who have HER2 positive breast cancer which has spread to the brain (metastasised) the main treatment options are as follows: Whole Brain Radiotherapy (WBRT), or Stereotactic Radiosurgery (SRS), or Neurosurgery (NS).
The aim of this study was to show that brain metastases are able to be controlled by SRS and/or NS without the need for WBRT. Although a modest sample size, study results show that Stereotactic radiosurgery (SRS) and/ or neurosurgery, provided good control with low toxicity for patients with metastatic HER2+ breast cancer brain metastases.
Link to publication: doi: 10.1016/j.breast.2024.103675
Primary Sponsor
Final Accrual
25
Closing Date of Accrual
22 December 2020
Trial Chairperson
Dr Claire Phillips, Peter MacCallum Cancer Centre, VIC
Trial Contact
LocalHero@trog.com.au
Clinical Trial Registration
Related Post
TROG 21.07 SOCRATES HCC Trial Expands Outreach
TRIAL IN FOCUS: 29 July 2025 We’ve extended the
Major milestone for BIG 3-07/TROG 07.01 DCIS Study
TRIAL UPDATE: 29 July 2025 A large international study
